KARDHealthcare · Biotechnology

KARD Stock Forecast: Kardigan, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$21

+3.55% on the day

The 4 Wall Street analysts covering Kardigan, Inc. hold a median 12-month price target of $43 — +105.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$2.0B

Ticker Nerd rank

0 / 100

Median analyst target

$43

Analysts covering

Total return, dividends reinvested

+3.9%

−8.4%

From high

−19.0%

From low

+6.3%

$20

$26

Range since 18 June 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

KARD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kardigan, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Issuance

Value

Growth

Accruals

Quality

Volatility

Momentum

Size (37): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 18 June 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts

4 Buy0 Hold0 Sell

Low $37Median $43High $51

The green dot is the last close — the median target sits +105.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 July 2026	Jefferies	Initiates	Buy	$40
13 July 2026	JP Morgan	Initiates	Overweight	$51
13 July 2026	Leerink Partners	Initiates	Outperform	$37
13 July 2026	TD Cowen	Initiates	Buy	$46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KARD appears on the weeks it earns a place.

Estimates

KARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Kardigan, Inc. (KARD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.6×
Price / sales: —
Price / book: −4.3×
EV / EBITDA: −5.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 76.7%
Return on assets: −49.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KARD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
KARDKardigan, Inc.	$2.0B	0
BRVEBraveheart Bio, Inc.	$1.9B	0
TSHATaysha Gene Therapies, Inc.	$1.9B	46
SRPTSarepta Therapeutics, Inc.	$2.0B	72
GHRSGH Research PLC	$1.9B	65
XNCRXencor, Inc.	$2.0B	83
AGIOAgios Pharmaceuticals, Inc.	$1.9B	81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kardigan, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KARD news & analysis

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Business Wire · 11 Aug 2026neutral

Kardigan, Inc. (Nasdaq: KARD) reported its second quarter 2026 financial results for the period ended June 30, 2026, and provided recent business updates. The announcement was made via Business Wire from the company's South San Francisco and Princeton locations.

Why it matters — This is Kardigan's official quarterly financial report, which KARD watchers would use to assess the company's most recent operating performance.

FAQ

Frequently asked questions about KARD stock

What is the KARD stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Kardigan, Inc. have a median 12-month price target of $43, with estimates ranging from $37 to $51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KARD stock a buy right now?

Of the 4 analysts covering Kardigan, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kardigan, Inc. 0 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KARD?

As at 22 Aug 2026, Kardigan, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (37 of 100).

Will KARD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +105.0% from the last close, and Ticker Nerd's factor model ranks Kardigan, Inc. 0 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KARD stock forecast for 2030?

No analyst covering Kardigan, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $51 over the next 12 months.

What does Kardigan, Inc. do?

Kardigan, Inc. is a clinical-stage biotechnology company focused on cardiovascular drug development.

What is the latest news on KARD?

The most recent item we track (Business Wire, 11 Aug 2026): "Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates". Kardigan, Inc. (Nasdaq: KARD) reported its second quarter 2026 financial results for the period ended June 30, 2026, and provided recent business updates. The announcement was made via Business Wire from the company's South San Francisco and Princeton locations.

Company

About Kardigan, Inc.

Kardigan, Inc. is a clinical-stage biotechnology company focused on cardiovascular drug development. It develops medicines aimed at the root causes of specific heart and vascular diseases, using patient data, clinical trial insights, and advanced analytics to identify responders and refine treatment strategies. The company’s work centers on targeted therapies for unmet needs in cardiology, including diseases where approved treatment options remain limited. Kardigan also combines internal research with licensing and collaborative development to build a portfolio of cardiovascular candidates. Based in South San Francisco, California, Kardigan operates as a heart health company serving the broader biopharmaceutical and healthcare ecosystem.

CEO Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA · 241 employees · United States · https://www.kardigan.bio